Basic information
- CAS
51781-21-6- Standard SMILES
CC(C)(C)NCC(O)COc1cccc2c1CCC(=O)N2.Cl- InChIKey
FYBXRCFPOTXTJF-UHFFFAOYSA-N- Molecular formula
- C16H25ClN2O3
- Average molar mass
- 328.83 g/mol
- Monoisotopic mass
- 328.1553704
Overview
Carteolol Hydrochloride is a synthetic quinolinone derivative, antihypertensive Carteolol Hydrochloride is a nonselective beta-adrenoceptor blocking agent for beta-1 and beta-2 receptors with no membrane-stabilizing activity but moderate intrinsic sympathomimetic effects. It is used for treatment of hypertension and certain arrhythmias, and as an anti-angina and antiglaucoma agent. (NCI04)
Names & identifiers
- Preferred name
- Carteolol Hydrochloride
- IUPAC
- 5-[3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydro-1H-quinolin-2-one;hydrochloride
- English name
- Carteolol hydrochloride
- Molecular formula
- C16H25ClN2O3
- Molecular weight
- 328.83
Names & synonyms
Show more names
Database identifiers
- CAS
51781-21-6- PubChem CID
- 40127
- DTXSID
DTXSID4045478- ChEMBL
CHEMBL1201002- UNII
- 4797W6I0T4
- EC Number
- 257-415-7
Properties
Computed structural properties
- Topological polar surface area
- 70.6 Ų
- Hydrogen bond donors
- 4
- Hydrogen bond acceptors
- 4
- Rotatable bonds
- 6
- Heavy atoms
- 22
- Formal charge
- 0
- Complexity
- 354
Experimental & physicochemical properties
Human Drugs
Breast Feeding; Lactation; Milk, Human; Adrenergic Beta-Antagonists; Antiglaucoma Agents
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Physicochemical properties
- Melting point
- 278 °C · 278°C
- storage temp.
- Refrigerator
- solubility
- 96 per · Soluble in water, sparingly soluble in methanol, slightly soluble in ethanol 96 per cent, practically insoluble in methylene chloride.
- form
- Solid
- color
- White to Off-White
- Merck
- 14 · 14,1866
- InChI
- InChI=1S/C16H24N2O3.ClH/c1-16(2,3)17-9-11(19)10-21-14-6-4-5-13-12(14)7-8-15(20)18-13;/h4-6,11,17,19H,7-10H2,1-3H3,(H,18,20);1H
- InChIKey
- FYBXRCFPOTXTJF-UHFFFAOYSA-N
- SMILES
- C12CCC(=O)NC=1C=CC=C2OCC(O)CNC(C)(C)C.Cl
- FDA UNII
- 4797 W6I0T4 · 4797W6I0T4
- Symbol(GHS)
- 7 · GHS07
- Signal word
- Warning
- Hazard statements
- 302 · H302
- Precautionary statements
- 301 · P301+P312+P330
- RTECS
- 8282000 · VC8282000
- HS Code
- 2933790002 · 2933790002
- Toxicity
- 50 in · LD50 in male mice, rats (mg/kg): 810, 1380 orally; 54.5, 158 i.v.; 380, 400 i.p. (Lang)
Safety & regulation
GHS classification
GHS Classification
This chemical does not meet GHS hazard criteria for 16.7% (1 of 6) of reports.
Warning
H302 (83.3%): Harmful if swallowed [Warning Acute toxicity, oral]
P203, P264, P264+P265, P270, P280, P301+P317, P305+P351+P338, P318, P330, P337+P317, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 6 reports by companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Hazard information
Toxicology
Safety data
- rtecs
- VC8282000
- hs_code
- 2933790002
- Toxicity
- LD50 in male mice, rats (mg/kg): 810, 1380 orally; 54.5, 158 i.v.; 380, 400 i.p. (Lang)
- Signal word
- Warning
- Symbol(GHS)
- GHS07
- Hazard statements
- H302
- Precautionary statements
- P301+P312+P330
Chemistry & industry
Pharmacology
FDA Pharmacological Classification
CARTEOLOL HYDROCHLORIDE
Adrenergic beta-Antagonists [MoA]; beta-Adrenergic Blocker [EPC]
MeSH Pharmacological Classification
Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety.
Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade.
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.
Drugs that inhibit the actions of the sympathetic nervous system by any mechanism. The most common of these are the ADRENERGIC ANTAGONISTS and drugs that deplete norepinephrine or reduce the release of transmitters from adrenergic postganglionic terminals (see ADRENERGIC AGENTS). Drugs that act in the central nervous system to reduce sympathetic activity (e.g., centrally acting alpha-2 adrenergic agonists, see ADRENERGIC ALPHA-AGONISTS) are included here.
Applications
Usesβ-Adrenergic blocker. Antihypertensive; antianginal; antiarrhythmic; antiglaucoma.
Upstream & downstream products
Downstream products
Suppliers100 total
Related reactions
No reaction records under the current filter.
Compound notes
Loading…